8-K
Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   November 30, 2004 (November 30, 2004)

Endo Pharmaceuticals Holdings Inc.


(Exact name of registrant as specified in its charter)
         
Delaware   001-15989   13-4022871

 
 
 
 
 
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification No.)
         
100 Painters Drive, Chadds Ford, PA       19317

 
     
 
(Address of principal executive offices)       (Zip Code)
     
Registrant’s telephone number, including area code   (610) 558-9800

Not Applicable


Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 


TABLE OF CONTENTS

Item 7.01. Regulation FD Disclosure.
Item 9.01. Financial Statements and Exhibits.
SIGNATURES
INDEX TO EXHIBITS
EX-99.1: SLIDE PRESENTATION


Table of Contents

Item 7.01. Regulation FD Disclosure.

On November 30, 2004, the Registrant intends to make a slide presentation at the Lazard Life Sciences Conference in New York, New York, a copy of which presentation is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(a)   Financial Statements of Business Acquired.

     Not applicable.

(b)   Pro Forma Financial Information.

     Not applicable.

(c)   Exhibits.
     
Exhibit Number
  Description
99.1
  Slide Presentation of Endo Pharmaceuticals Holdings Inc. dated November 30, 2004

 


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

         
  ENDO PHARMACEUTICALS HOLDINGS INC.
(Registrant)
 
 
  By:   /s/ CAROL A. AMMON    
    Name:   Carol A. Ammon   
    Title:   Chairman & Chief Executive Officer   
 

Dated: November 30, 2004

 


Table of Contents

INDEX TO EXHIBITS

     
Exhibit No.
  Description
99.1
  Slide Presentation of Endo Pharmaceuticals Holdings Inc. dated November 30, 2004